What is Amgen?
Founded in 1980 as Applied Molecular Genetics, Amgen Inc. has been a pioneer in the biotechnology industry, establishing its headquarters in Thousand Oaks, California. The company is recognized for its leadership in scientific innovation and its role in developing groundbreaking therapies. Amgen's operations span various therapeutic areas, leveraging cutting-edge research and development to address unmet medical needs globally. Its long-standing presence and consistent advancements position it as a key player in the American and international biotech markets.
How much funding has Amgen raised?
Amgen has raised a total of $2B across 2 funding rounds:
Debt
$19M
Debt
$2B
Debt (1980): $19M, investors not publicly disclosed
Debt (2022): $2B led by Citigroup
Key Investors in Amgen
Citigroup
Citigroup Inc. is a leading global financial services company headquartered in New York City, New York. One of the world's largest banks, Citi provides a broad range of financial products and services including consumer banking, corporate and investment banking, securities brokerage, trade finance, and wealth management to individuals, corporations, governments, and institutions in over 160 countries.
What's next for Amgen?
The recent major strategic investment signifies Amgen's ongoing commitment to expanding its research capabilities and market reach. This capital injection is likely to fuel further innovation in drug discovery and development, potentially leading to new therapeutic breakthroughs. As a leader in biotechnology, Amgen is poised to continue its growth trajectory, navigating the complexities of the enterprise-level funding environment to maintain its competitive edge and deliver value to patients and stakeholders.
See full Amgen company page
